Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22)

International Journal of Hematology

Volumn 95, Issue 5, 2012, Pages 577-580

  Kawashima, Nozomu ^a   Shimada, Akira ^b   Taketani, Takeshi ^c   Hayashi, Yasuhide ^d   Yoshida, Nao ^a   Matsumoto, Kimikazu ^a   Takahashi, Yoshiyuki ^b   Kojima, Seiji ^b   Kato, Koji ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIMANE UNIVERSITY HOSPITAL   (Japan)

^d Gumna Children S Medical Center   (Japan)

Author keywords

AML; Eosinophilia; Pediatric; RUNX1 CBFA2T3; t(16; 21)(q24; q22)

Indexed keywords

CORE BINDING FACTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNXT1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CASE REPORT; CHILD; CHILDHOOD LEUKEMIA; CHIMERA; CHROMOSOME TRANSLOCATION; EOSINOPHILIA; HUMAN; MALE; PRESCHOOL CHILD; PROGNOSIS; RARE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW; CHILD; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 21; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EOSINOPHILIA; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84862897867     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1044-7     Document Type: Article

References (15)

1. Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cyto- morphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. Leukemia. 2007;21(4):725-31. (Pubitemid 46444556)
2. Tobal K, Johnson PR, Saunders MJ, Harrison CJ, Liu Yin JA. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol. 1995;91(1):104-8.
3. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102(2):462-9. (Pubitemid 36841961)
4. Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo HB, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96(10): 1478-87.
5. Raimondi SC, Kalwinsky DK, Hayashi Y, Behm FG, Mirro J, Williams DL. Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1989;40(1):13-27. (Pubitemid 19218441)
6. Kondoh K, Nakata Y, Furuta T, Hosoda F, Gamou T, Kurosawa Y, et al. A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene. Leuk Lymphoma. 2002;43(2):415-20. (Pubitemid 34202124)
7. Frascella E, Zampieron C, Sainati L, Casula L, Pasquali F, Mura R, et al. AML1-MTG16 gene rearrangement in a pediatric therapy related AML after Ewing sarcoma: a case discussion and review of literature. Cancer Therapy. 2005;3(A):285-92.
8. Park IJ, Park JE, Kim HJ, Jung HJ, Lee WG, Cho SR. Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature. Cancer Genet Cytogenet. 2010;196(1):105-8.
9. De Braekeleer E, Douet-Guilbert N, Le Bris MJ, Morel F, Ferec C, De Braekeleer M. RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature. Cancer Genet Cytogenet. 2008;185(1): 47-50. (Pubitemid 352010361)
10. Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-13.
11. Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, et al. The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood. 1998;91(11):4028-37. (Pubitemid 28261962)
12. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene. 2004;23(24):4198-208. (Pubitemid 38765135)
13. Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K, et al. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol. 1998;18(2):846-58. (Pubitemid 28063418)
14. Monma F, Nishii K, Lorenzo F, Usui E, Ueda Y, Watanabe Y, et al. Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia. Eur J Haematol. 2006; 76(1):18-22.
15. Agarwal R, Vishnubhatla S, Gupta R, Bakhshi S. Diagnostic and follow-up eosinophilia is not predictive of outcome in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2011;33(2): e51-3.